BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease that arises as a result of the interaction between genetic and environmental factors. A growing body of research suggests that genetic variants within immune-related genes can influence the risk of developing the disease and affect drug response. MATERIALS AND METHODS: To test this hypothesis, we carried out a comprehensive two-stage case-control study in a White population of 1239 White RA patients and 1229 healthy controls to investigate whether 49 single nucleotide polymorphisms within or near 17 immune-related genes modulate the risk of developing RA and antitumor necrosis factor (anti-TNF) drug response. RESULTS: Logistic regression analyses showed that carriers of the IL4rs2070874T and IL4rs2243250T and IL8RBrs1126580A alleles or the IL8RBrs2230054C/C genotype had a significantly increased risk of developing RA [odds ratio (OR)=1.37, 95% confidence interval (CI) 1.13-1.67, P=0.0016; OR=1.24, 95% CI 1.03-1.49, P=0.020; OR=1.23, 95% CI 1.08-1.41, P=0.002 and OR=1.19, 95% CI 1.04-1.36, P=0.01, respectively]. The association of the IL4 variants was further supported by a meta-analysis including 7150 individuals (P =0.0010), whereas the involvement of the IL8RB locus in determining the susceptibility to RA was also supported by gene-gene interaction analyses that identified significant two-locus and three-locus interaction models including IL8RB variants that act synergistically to increase the risk of the disease (P=0.014 and 0.018). Interestingly, we also found that patients harbouring the IFNGrs2069705C allele showed a significantly better response to anti-TNF drugs than those patients carrying the wild-type allele (P=0.0075). CONCLUSIONS: Our data suggest that IL4 and IL8RB loci may have a small-effect genetic impact on the risk of developing RA, whereas IFNG might be involved in modulating the response to anti-TNF drugs.
BACKGROUND:Rheumatoid arthritis (RA) is a chronic autoimmune disease that arises as a result of the interaction between genetic and environmental factors. A growing body of research suggests that genetic variants within immune-related genes can influence the risk of developing the disease and affect drug response. MATERIALS AND METHODS: To test this hypothesis, we carried out a comprehensive two-stage case-control study in a White population of 1239 White RA patients and 1229 healthy controls to investigate whether 49 single nucleotide polymorphisms within or near 17 immune-related genes modulate the risk of developing RA and antitumor necrosis factor (anti-TNF) drug response. RESULTS: Logistic regression analyses showed that carriers of the IL4rs2070874T and IL4rs2243250T and IL8RBrs1126580A alleles or the IL8RBrs2230054C/C genotype had a significantly increased risk of developing RA [odds ratio (OR)=1.37, 95% confidence interval (CI) 1.13-1.67, P=0.0016; OR=1.24, 95% CI 1.03-1.49, P=0.020; OR=1.23, 95% CI 1.08-1.41, P=0.002 and OR=1.19, 95% CI 1.04-1.36, P=0.01, respectively]. The association of the IL4 variants was further supported by a meta-analysis including 7150 individuals (P =0.0010), whereas the involvement of the IL8RB locus in determining the susceptibility to RA was also supported by gene-gene interaction analyses that identified significant two-locus and three-locus interaction models including IL8RB variants that act synergistically to increase the risk of the disease (P=0.014 and 0.018). Interestingly, we also found that patients harbouring the IFNGrs2069705C allele showed a significantly better response to anti-TNF drugs than those patients carrying the wild-type allele (P=0.0075). CONCLUSIONS: Our data suggest that IL4 and IL8RB loci may have a small-effect genetic impact on the risk of developing RA, whereas IFNG might be involved in modulating the response to anti-TNF drugs.
Authors: Hyun Kyung Park; Su Kang Kim; Hae Yong Kweon; Kwan Gill Lee; Mariadhas Valan Arasu; Young Ock Kim Journal: Saudi J Biol Sci Date: 2016-01-11 Impact factor: 4.219
Authors: Jose M Sánchez-Maldonado; Rafael Cáliz; Luz Canet; Rob Ter Horst; Olivier Bakker; Alfons A den Broeder; Manuel Martínez-Bueno; Helena Canhão; Ana Rodríguez-Ramos; Carmen B Lupiañez; María José Soto-Pino; Antonio García; Eva Pérez-Pampin; Alfonso González-Utrilla; Alejandro Escudero; Juana Segura-Catena; Romana T Netea-Maier; Miguel Ángel Ferrer; Eduardo Collantes-Estevez; Miguel Ángel López Nevot; Yang Li; Manuel Jurado; João E Fonseca; Mihai G Netea; Marieke J H Coenen; Juan Sainz Journal: Sci Rep Date: 2019-10-15 Impact factor: 4.379
Authors: Jose Manuel Sánchez-Maldonado; Rafael Cáliz; Miguel Ángel López-Nevot; Antonio José Cabrera-Serrano; Ana Moñiz-Díez; Helena Canhão; Rob Ter Horst; Luca Quartuccio; Signe B Sorensen; Bente Glintborg; Merete L Hetland; Ileana Filipescu; Eva Pérez-Pampin; Pablo Conesa-Zamora; Jerzy Swierkot; Alfons A den Broeder; Salvatore De Vita; Eva Rabing Brix Petersen; Yang Li; Miguel A Ferrer; Alejandro Escudero; Mihai G Netea; Marieke J H Coenen; Vibeke Andersen; João E Fonseca; Manuel Jurado; Katarzyna Bogunia-Kubik; Eduardo Collantes; Juan Sainz Journal: Front Immunol Date: 2021-10-27 Impact factor: 7.561
Authors: Nadia M T Roodenrijs; Paco M J Welsing; Joël van Roon; Jan L M Schoneveld; Marlies C van der Goes; György Nagy; Michael J Townsend; Jacob M van Laar Journal: Rheumatology (Oxford) Date: 2022-08-30 Impact factor: 7.046
Authors: Jose Manuel Sánchez-Maldonado; Manuel Martínez-Bueno; Helena Canhão; Rob Ter Horst; Sonia Muñoz-Peña; Ana Moñiz-Díez; Ana Rodríguez-Ramos; Alejandro Escudero; Signe B Sorensen; Merete L Hetland; Miguel A Ferrer; Bente Glintborg; Ileana Filipescu; Eva Pérez-Pampin; Pablo Conesa-Zamora; Antonio García; Alfons den Broeder; Salvatore De Vita; Svend Erik Hove Jacobsen; Eduardo Collantes; Luca Quartuccio; Mihai G Netea; Yang Li; João E Fonseca; Manuel Jurado; Miguel Ángel López-Nevot; Marieke J H Coenen; Vibeke Andersen; Rafael Cáliz; Juan Sainz Journal: Sci Rep Date: 2020-03-09 Impact factor: 4.379